Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emavusertib - Aurigene Oncology/Curis

X
Drug Profile

Emavusertib - Aurigene Oncology/Curis

Alternative Names: AU 4948; CA 4948

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Curis; University of Leipzig
  • Class Amides; Amines; Antianaemics; Antineoplastics; Antirheumatics; Morpholines; Oxazoles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Clk dual-specificity kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia
  • Phase I/II Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I Gastric cancer; Oesophageal cancer
  • Preclinical Adenocarcinoma; Rheumatoid arthritis

Most Recent Events

  • 05 Jun 2024 National Cancer Institute plans a phase I trial for Urogenital cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) (PO), in August 2024 (NCT06439836)
  • 14 May 2024 Efficacy data from the phase I/II TakeAim trial in Acute myeloid leukaemia and Myelodysplastic syndromes released by Curis
  • 30 Apr 2024 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Metastatic disease) in USA (PO) (NCT05669352)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top